Mihaylova R, Momekova D, Elincheva V, Momekov G
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770542
PMC: 11677665.
DOI: 10.3390/ph17121701.
Liu L, Soler J, Reckamp K, Sankar K
Int J Mol Sci. 2024; 25(18).
PMID: 39337530
PMC: 11432526.
DOI: 10.3390/ijms251810046.
Taylor C, Patterson K, Friedman D, Bacot S, Feldman G, Wang T
Cancers (Basel). 2024; 16(17).
PMID: 39272928
PMC: 11393896.
DOI: 10.3390/cancers16173071.
Weiten R, Bernhardt M, Niemann M, Kristiansen G, Grunwald V, Ritter M
J Cell Mol Med. 2024; 28(14):e18572.
PMID: 39072867
PMC: 11284121.
DOI: 10.1111/jcmm.18572.
Tang Q, Li H, Zhao X, Li Z, Ma C, Zhou S
World J Oncol. 2024; 15(4):527-542.
PMID: 38993251
PMC: 11236369.
DOI: 10.14740/wjon1853.
Progress in the study of antibody-drug conjugates for the treatment of cervical cancer.
Zhai C, Cui Y, Guo L, Chen C, Song Y, Zhong J
Front Oncol. 2024; 14:1395784.
PMID: 38903711
PMC: 11187480.
DOI: 10.3389/fonc.2024.1395784.
Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.
Weiten R, Niemann M, Below E, Friker L, Ralser D, Toma M
Cancer Med. 2024; 13(12):e7320.
PMID: 38895886
PMC: 11185941.
DOI: 10.1002/cam4.7320.
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
Wu Y, Zhu M, Sun B, Chen Y, Huang Y, Gai J
J Nanobiotechnology. 2024; 22(1):256.
PMID: 38755613
PMC: 11097425.
DOI: 10.1186/s12951-024-02521-5.
Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Klumper N, Tran N, Zschabitz S, Hahn O, Buttner T, Roghmann F
J Clin Oncol. 2024; 42(20):2446-2455.
PMID: 38657187
PMC: 11227306.
DOI: 10.1200/JCO.23.01983.
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y
J Cancer Res Clin Oncol. 2024; 150(4):182.
PMID: 38592548
PMC: 11003883.
DOI: 10.1007/s00432-024-05717-2.
Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice.
Lefort F, Rhanine Y, Larroquette M, Domblides C, Heraudet L, Sionneau B
Cancers (Basel). 2023; 15(23).
PMID: 38067262
PMC: 10705302.
DOI: 10.3390/cancers15235558.
Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS.
Nanamiya T, Takane K, Yamaguchi K, Okawara Y, Arakawa M, Saku A
Oncol Rep. 2023; 51(1).
PMID: 38063270
PMC: 10739986.
DOI: 10.3892/or.2023.8676.
Expression of nectin-4 in prostate cancer.
Ordu M, Karaaslan M, Sirin M, Yilmaz M
North Clin Istanb. 2023; 10(5):583-588.
PMID: 37829757
PMC: 10565758.
DOI: 10.14744/nci.2023.36034.
Temporary Tumor Shrinkage Following Enfortumab Vedotin Therapy for Metastatic Urothelial Carcinoma After Radical Cystectomy With Neoadjuvant Chemotherapy: A Case Report.
Namiki S, Kato D, Iinuma K, Nakane K, Koie T
Cureus. 2023; 15(8):e42954.
PMID: 37667727
PMC: 10475292.
DOI: 10.7759/cureus.42954.
Nectin-4 as a Predictive Marker for Poor Prognosis of Endometrial Cancer with Mismatch Repair Impairment.
Chang H, Park Y, Choi J, Kim J, Kim J, Kim H
Cancers (Basel). 2023; 15(10).
PMID: 37345201
PMC: 10216516.
DOI: 10.3390/cancers15102865.
Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers.
Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G
Front Mol Biosci. 2023; 10:1149973.
PMID: 37251078
PMC: 10213976.
DOI: 10.3389/fmolb.2023.1149973.
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W, Fang P, Yu D, Ren H, You M, Yin L
Mol Cancer Ther. 2023; 22(8):913-925.
PMID: 37196158
PMC: 10390865.
DOI: 10.1158/1535-7163.MCT-22-0743.
Diagnostic and Prognostic Roles of Urine Nectin-2 and Nectin-4 in Human Bladder Cancer.
Miyake M, Nishimura N, Ohnishi S, Oda Y, Owari T, Ohnishi K
Cancers (Basel). 2023; 15(9).
PMID: 37174031
PMC: 10177453.
DOI: 10.3390/cancers15092565.
Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy.
Moritoh K, Shoji K, Amagai Y, Fujiyuki T, Sato H, Yoneda M
Cancer Sci. 2023; 114(5):2158-2168.
PMID: 36715555
PMC: 10154881.
DOI: 10.1111/cas.15740.
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Tassinari E, Mollica V, Nuvola G, Marchetti A, Rosellini M, Massari F
Cancer Manag Res. 2022; 14:1945-1960.
PMID: 35720644
PMC: 9205436.
DOI: 10.2147/CMAR.S287904.